Abstract: A water treatment system includes an actinic radiation reactor and at least one ultraviolet (UV) lamp disposed within a quartz tube within the actinic radiation reactor. The at least one UV lamp includes a lamp tube including a gas that emits ultraviolet light responsive to electrical excitation, a first pinch extending from a first end of the lamp tube and a second pinch extending from a second end of the lamp tube, and a first end cap coupled to the first pinch and a second end cap coupled to the second pinch. The first end cap and second end cap are dimensioned to center the lamp tube coaxially within the quartz tube.

Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.

Abstract: A compound represented by the general formula (1) or a salt thereof, which has a superior IRAK-4 inhibitory activity, and is useful as active ingredients of medicaments for prophylactic treatment and/or therapeutic treatment of diseases relating to IRAK-4 inhibition.

Abstract: Implantable biosensors and methods of making and using such biosensors are disclosed. The biosensors can be micro-devices, for example, micro-sized bead implants having an associated gyroscope, accelerometer and/or magnetometer to detect and transmit changes in the position of the biosensor following implantation. The biosensors can be implanted into a subject’s bone and/or a subject’s prosthesis to detect, for example, changes in position or orientation of a prosthetic implant that can indicate loosening or potential onset of structural failures. Devices for implantation of biosensors, e.g., kinematic sensors, into bone are also disclosed as well as methods and systems for measuring or monitoring physiological kinematics.

Abstract: A scraper assembly configured to traverse an exterior surface of a tubular member is disclosed. The scraper assembly includes a casing constructed and arranged to drive the scraper assembly to traverse the exterior surface of the tubular member and a primary ring fixed to the casing, having a plurality of projections formed of a semi-rigid material extending inward toward the exterior surface of the tubular member. A water treatment system including the scraper assembly is also disclosed. A method of retrofitting a water treatment system including providing the scraper assembly is also disclosed. A method of removing organic material fouling from an exterior surface of a quartz sleeve is also disclosed. The method includes directing the scraper assembly to traverse the exterior surface of the quartz sleeve.

Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

Abstract: A water treatment system includes an actinic radiation reactor and at least one ultraviolet (UV) lamp disposed within a quartz tube within the actinic radiation reactor. The at least one UV lamp includes a lamp tube including a gas that emits ultraviolet light responsive to electrical excitation, a first pinch extending from a first end of the lamp tube and a second pinch extending from a second end of the lamp tube, and a first end cap coupled to the first pinch and a second end cap coupled to the second pinch. The first end cap and second end cap are dimensioned to center the lamp tube coaxially within the quartz tube.

Abstract: A downhole device (15) comprising: a body (10) with a bore; at least one wheel (20) or other retained component; an engagement member (40) for engaging the wheel with the body. A retaining member (31) retains the engagement member (40) in place, the retaining member (31) extending along the body (10) and in the line of the main axis of the engagement member (40) so that it abuts. Embodiments allow for more convenient and more reliable retaining of wheels or other components in the device especially reducing the need for using threaded connections, which are prone to failure.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.

Abstract: Compounds of formula (I) are A2B receptor antagonists: Wherein R1 is optionally substituted aryl or an optionally substituted 5- or 6-membered heteroaryl ring; R2 and R3 are independently selected from hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl-(C1-C6)-alkyl, aryl-(C1-C6)-alkyl optionally substituted in the ring part thereof, a 5- or 6-membered monocyclic heterocyclic group optionally linked via a C1-C6 alkylene chain and optionally substituted in the ring part thereof, benzimidazol-2-yl-methyl, pyrid-3-yl-carbonyl, or (1-methyl-piperidin-4-yl)-carbonyl-methyl; or R2 and R3 taken together with the nitrogen atom to which they are attached form an optionally substituted 5- or 6-membered ring; R4 is C1-C3 alkyl, C2-C3 alkenyl, —N(—R5)—R6, or optionally substituted heteroarylmethylamino; and R5 and R6 are independently selected from hydrogen or C1-C3 alkyl; or R5 and R6 taken together with the nitrogen atom to which they are attached form an optionally substituted 4- to 6-membered saturated rin

Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

Abstract: The inventions relates to compounds of (I) and therapeutic uses thereof: (I) The terms Z, Y, and R1 are as defined in the claims.

Abstract: A downhole device (15) comprising: a body (10) with a bore; at least one wheel (20) or other retained component; an engagement member (40) for engaging the wheel with the body. A retaining member (31) retains the engagement member (40) in place, the retaining member (31) extending along the body (10) and in the line of the main axis of the engagement member (40) so that it abuts.

Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are. disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

Abstract: Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: wherein R1, is a group of formula (IA): —Ar1-(Alk1)p-(Z)r-(Alk2)s-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1 and Alk2 are optionally substituted divalent C1-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is —O—, —S—, —(C?O)—, —(C?S)—, —SO.sub.

Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.

Abstract: Compounds of formula (I) that are capable of acting as purine receptor antagonists, pharmaceutical compositions including the compounds, and methods of making the compounds, are disclosed. The compounds and compositions can be used in treating or preventing disorders related to purine receptor hyperfunctioning.